Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,600
Employees17,600
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,600
Employees17,600

GILD Key Statistics

Market cap
146.70B
Market cap146.70B
Price-Earnings ratio
23.23
Price-Earnings ratio23.23
Dividend yield
2.69%
Dividend yield2.69%
Average volume
8.58M
Average volume8.58M
High today
$118.35
High today$118.35
Low today
$115.76
Low today$115.76
Open price
$117.12
Open price$117.12
Volume
6.53M
Volume6.53M
52 Week high
$121.83
52 Week high$121.83
52 Week low
$84.17
52 Week low$84.17

GILD News

Simply Wall St 1d
How Will the Trump HIV Partnership Impact Gilead Sciences Valuation in 2025?

If you are standing at the crossroads, trying to decide what to do with Gilead Sciences stock, you are in good company. This biotech giant has made impressive m...

How Will the Trump HIV Partnership Impact Gilead Sciences Valuation in 2025?
Benzinga 2d
Gilead Reaches Settlement To Block Biktarvy Generics Until 2036

Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs L...

Gilead Reaches Settlement To Block Biktarvy Generics Until 2036
Investor's Business Daily 2d
Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump

Gilead stock popped Monday after the biotech giant said it signed deals with three generic drugmakers to delay their Biktarvy copycats for two years. RBC Capit...

Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

More GILD News

Seeking Alpha 2d
Gilead Sciences settles patent litigations related to Biktarvy

Gilead Sciences (NASDAQ:GILD) has reached settlement agreements with Lupin, Cipla, and Laurus Labs to resolve patent disputes related to Biktarvy, a medication...

Gilead Sciences settles patent litigations related to Biktarvy
TipRanks 2d
Gilead settles patent litigations with Biktarvy ANDA filerers

In a regulatory filing, Gilead (GILD) Sciences disclosed that on October 6, Gilead announced that it has entered into settlement agreements to resolve the paten...

Simply Wall St 5d
Should Gilead’s Partnerships and CDC Support Shift Investor Focus Toward Growth in Oncology and HIV?

On September 22, Kymera Therapeutics announced an exclusive collaboration with Gilead Sciences to develop a new molecular glue degrader program for oncology, sh...

Should Gilead’s Partnerships and CDC Support Shift Investor Focus Toward Growth in Oncology and HIV?
TipRanks 6d
Gilead Sciences: Strong Growth Potential Driven by Yeztugo Launch and Strategic Positioning

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences yesterday and set a price target of $143.00. Elevate Your Investing Strategy: Ta...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.